MedTrace Logo

Treatment of Diabetes After Gastric Bypass With Sitagliptin

NCT01512797 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2019-01-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess whether Januvia (sitagliptin phosphate 100mg) is safe and effective for the treatment of Type 2 Diabetes in patients who have had Gastric Bypass.

Conditions

Interventions

DRUG

Sitagliptin phosphate

100 mg/day orally

OTHER

Placebo

1 Placebo Pill per day

Sponsors & Collaborators

Principal Investigators

  • Blandine Laferrere, MD · New York Obesity Nutrition Research Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2016-08-31
Completion
2016-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01512797 on ClinicalTrials.gov